HIF Hydroxylase Pathways in Cardiovascular Physiology and Medicine

Circulation Research

Volumn 117, Issue 1, 2015, Pages 65-79

  Bishop, Tammie ^a   Ratcliffe, Peter J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

dioxygenases; hypoxia; hypoxia inducible factor; prolyl hydroxylases

Indexed keywords

DIOXYGENASE; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR PROLINE DIOXYGENASE; IRON; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; EGLN1 PROTEIN, HUMAN; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; HIF1AN PROTEIN, HUMAN; ISOPROTEIN; MIXED FUNCTION OXIDASE; OXYGEN; REPRESSOR PROTEIN; VON HIPPEL LINDAU PROTEIN;

ACUTE HEART INFARCTION; APOPTOSIS; CARBOXY TERMINAL SEQUENCE; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CORONARY ARTERY BLOOD FLOW; ENDOTHELIUM CELL; ENERGY METABOLISM; FETUS DEVELOPMENT; FETUS OUTCOME; GENETIC PREDISPOSITION; HEART DEVELOPMENT; HEART FUNCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HUMAN GENETICS; HYPOXEMIA; HYPOXIA; ISCHEMIC PRECONDITIONING; LUNG ARTERY PRESSURE; LUNG CIRCULATION; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SYSTEMIC CIRCULATION; TRANSCRIPTION INITIATION; ADAPTATION; ALTITUDE; ANIMAL; ANOXIA; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; CELL HYPOXIA; CONGENITAL HEART MALFORMATION; DEFICIENCY; EMBRYOLOGY; ENZYMOLOGY; GENETICS; HEART; HEART INFARCTION PREVENTION; HYDROXYLATION; METABOLISM; MOUSE; PHYSIOLOGY; POLYCYTHEMIA; PROTEIN PROCESSING;

ADAPTATION, PHYSIOLOGICAL; ALTITUDE; ANIMALS; ANOXIA; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; CELL HYPOXIA; HEART; HEART DEFECTS, CONGENITAL; HUMANS; HYDROXYLATION; HYPERTENSION, PULMONARY; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; HYPOXIA-INDUCIBLE FACTOR-PROLINE DIOXYGENASES; IRON; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MICE; MIXED FUNCTION OXYGENASES; OXYGEN; POLYCYTHEMIA; PROTEIN ISOFORMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; REPRESSOR PROTEINS; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84942848861     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.117.305109     Document Type: Review

References (146)

1. Maxwell PH, Pugh CW, Ratcliffe PJ. Inducible operation of the erythropoietin 3' enhancer in multiple cell lines: evidence for a widespread oxygen- sensing mechanism. Proc Natl Acad Sci U S A. 1993;90:2423-2427.
2. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol. 1992;12:5447-5454.
3. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A. 1995;92:5510-5514.
4. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, von Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, Ratcliffe PJ. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001;292:468-472. doi: 10.1126/science.1059796.
5. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS, Kaelin WG Jr. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001;292:464-468. doi: 10.1126/science.1059817.
6. Epstein AC, Gleadle JM, McNeill LA, et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell. 2001;107:43-54.
7. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science. 2001;294:1337-1340. doi: 10.1126/ science.1066373.
8. Loenarz C, Coleman ML, Boleininger A, Schierwater B, Holland PW, Ratcliffe PJ, Schofield CJ. The hypoxia-inducible transcription factor pathway regulates oxygen sensing in the simplest animal, Trichoplax adhaerens. EMBO Rep. 2011;12:63-70. doi: 10.1038/embor.2010.170.
9. Hu CJ, Wang LY, Chodosh LA, Keith B, Simon MC. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol. 2003;23:9361-9374.
10. Schödel J, Oikonomopoulos S, Ragoussis J, Pugh CW, Ratcliffe PJ, Mole DR. High-resolution genome-wide mapping of HIF-binding sites by ChIPseq. Blood. 2011;117:e207-e217. doi: 10.1182/blood-2010-10-314427.
11. Mahon PC, Hirota K, Semenza GL. FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 2001;15:2675-2686. doi: 10.1101/gad.924501.
12. Lando D, Peet DJ, Whelan DA, Gorman JJ, Whitelaw ML. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science. 2002;295:858-861. doi: 10.1126/science.1068592.
13. Lando D, Peet DJ, Gorman JJ, Whelan DA, Whitelaw ML, Bruick RK. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev. 2002;16:1466-1471. doi: 10.1101/gad.991402.
14. Hewitson KS, McNeill LA, Riordan MV, Tian YM, Bullock AN, Welford RW, Elkins JM, Oldham NJ, Bhattacharya S, Gleadle JM, Ratcliffe PJ, Pugh CW, Schofield CJ. Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. J Biol Chem. 2002;277:26351-26355. doi: 10.1074/jbc.C200273200.
15. Loenarz C, Schofield CJ. Physiological and biochemical aspects of hydroxylations and demethylations catalyzed by human 2-oxoglutarate oxygenases. Trends Biochem Sci. 2011;36:7-18. doi: 10.1016/j.tibs.2010.07.002.
16. Fisher SA, Burggren WW. Role of hypoxia in the evolution and development of the cardiovascular system. Antioxid Redox Signal. 2007;9:1339-1352. doi: 10.1089/ars.2007.1704.
17. Berra E, Benizri E, Ginouvès A, Volmat V, Roux D, Pouysségur J. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J. 2003;22:4082-4090. doi: 10.1093/emboj/cdg392.
18. Appelhoff RJ, Tian YM, Raval RR, Turley H, Harris AL, Pugh CW, Ratcliffe PJ, Gleadle JM. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem. 2004;279:38458-38465. doi: 10.1074/jbc.M406026200.
19. Semenza GL. Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. Annu Rev Pathol. 2014;9:47-71. doi: 10.1146/ annurev-pathol-012513-104720.
20. Ratcliffe PJ. Oxygen sensing and hypoxia signalling pathways in animals: the implications of physiology for cancer. J Physiol. 2013;591:2027-2042. doi: 10.1113/jphysiol.2013.251470.
21. Dunwoodie SL. The role of hypoxia in development of the Mammalian embryo. Dev Cell. 2009;17:755-773. doi: 10.1016/j.devcel.2009.11.008.
22. Patterson AJ, Zhang L. Hypoxia and fetal heart development. Curr Mol Med. 2010;10:653-666.
23. Lee YM, Jeong CH, Koo SY, Son MJ, Song HS, Bae SK, Raleigh JA, Chung HY, Yoo MA, Kim KW. Determination of hypoxic region by hypoxia marker in developing mouse embryos in vivo: a possible signal for vessel development. Dev Dyn. 2001;220:175-186. doi: 10.1002/1097-0177(20010201)220:2<175::AID-DVDY1101>3.0.CO;2-F.
24. Buckingham M, Meilhac S, Zaffran S. Building the mammalian heart from two sources of myocardial cells. Nat Rev Genet. 2005;6:826-835. doi: 10.1038/nrg1710.
25. Sugishita Y, Leifer DW, Agani F, Watanabe M, Fisher SA. Hypoxiaresponsive signaling regulates the apoptosis-dependent remodeling of the embryonic avian cardiac outflow tract. Dev Biol. 2004;273:285-296. doi: 10.1016/j.ydbio.2004.05.036.
26. Sugishita Y, Watanabe M, Fisher SA. Role of myocardial hypoxia in the remodeling of the embryonic avian cardiac outflow tract. Dev Biol. 2004;267:294-308. doi: 10.1016/j.ydbio.2003.11.017.
27. Krishnan J, Ahuja P, Bodenmann S, Knapik D, Perriard E, Krek W, Perriard JC. Essential role of developmentally activated hypoxia-inducible factor 1alpha for cardiac morphogenesis and function. Circ Res. 2008;103:1139-1146. doi: 10.1161/01.RES.0000338613.89841.c1.
28. Kenchegowda D, Liu H, Thompson K, Luo L, Martin SS, Fisher SA. Vulnerability of the developing heart to oxygen deprivation as a cause of congenital heart defects. J Am Heart Assoc. 2014;3:e000841. doi: 10.1161/JAHA.114.000841.
29. Yamashita T, Ohneda O, Nagano M, Iemitsu M, Makino Y, Tanaka H, Miyauchi T, Goto K, Ohneda K, Fujii-Kuriyama Y, Poellinger L, Yamamoto M. Abnormal heart development and lung remodeling in mice lacking the hypoxia-inducible factor-related basic helix-loop-helix PAS protein NEPAS. Mol Cell Biol. 2008;28:1285-1297. doi: 10.1128/ MCB.01332-07.
30. Jain S, Maltepe E, Lu MM, Simon C, Bradfield CA. Expression of ARNT, ARNT2, HIF1 alpha, HIF2 alpha and Ah receptor mRNAs in the developing mouse. Mech Dev. 1998;73:117-123.
31. Compernolle V, Brusselmans K, Franco D, Moorman A, Dewerchin M, Collen D, Carmeliet P. Cardia bifida, defective heart development and abnormal neural crest migration in embryos lacking hypoxia-inducible factor-1alpha. Cardiovasc Res. 2003;60:569-579.
32. Kotch LE, Iyer NV, Laughner E, Semenza GL. Defective vascularization of HIF-1alpha-null embryos is not associated with VEGF deficiency but with mesenchymal cell death. Dev Biol. 1999;209:254-267. doi: 10.1006/ dbio.1999.9253.
33. Iyer NV, Kotch LE, Agani F, Leung SW, Laughner E, Wenger RH, Gassmann M, Gearhart JD, Lawler AM, Yu AY, Semenza GL. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev. 1998;12:149-162.
34. Peng J, Zhang L, Drysdale L, Fong GH. The transcription factor EPAS-1/ hypoxia-inducible factor 2alpha plays an important role in vascular remodeling. Proc Natl Acad Sci U S A. 2000;97:8386-8391. doi: 10.1073/ pnas.140087397.
35. Tian H, Hammer RE, Matsumoto AM, Russell DW, McKnight SL. The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. Genes Dev. 1998;12:3320-3324.
36. Scortegagna M, Ding K, Oktay Y, Gaur A, Thurmond F, Yan LJ, Marck BT, Matsumoto AM, Shelton JM, Richardson JA, Bennett MJ, Garcia JA. Multiple organ pathology, metabolic abnormalities and impaired homeostasis of reactive oxygen species in Epas1-/- mice. Nat Genet. 2003;35:331-340. doi: 10.1038/ng1266.
37. Compernolle V, Brusselmans K, Acker T, et al. Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med. 2002;8:702-710. doi: 10.1038/nm721.
38. Bamforth SD, Braganca J, Eloranta JJ, Murdoch JN, Marques FIR, Kranc KR, Farza H, Henderson DJ, Hurst HC, Bhattacharya S. Cardiac malformations, adrenal agenesis, neural crest defects and exencephaly in mice lacking Cited2, a new Tfap2 co-activator. Nature Genetics. 2001;10:1-6.
39. Xu B, Doughman Y, Turakhia M, Jiang W, Landsettle CE, Agani FH, Semenza GL, Watanabe M, Yang YC. Partial rescue of defects in Cited2- deficient embryos by HIF-1alpha heterozygosity. Dev Biol. 2007;301:130-140. doi: 10.1016/j.ydbio.2006.08.072.
40. Takeda K, Ho VC, Takeda H, Duan LJ, Nagy A, Fong GH. Placental but not heart defects are associated with elevated hypoxia-inducible factor alpha levels in mice lacking prolyl hydroxylase domain protein 2. Mol Cell Biol. 2006;26:8336-8346. doi: 10.1128/MCB.00425-06.
41. MacDonald ST, Bamforth SD, Bragança J, Chen CM, Broadbent C, Schneider JE, Schwartz RJ, Bhattacharya S. A cell-autonomous role of Cited2 in controlling myocardial and coronary vascular development. Eur Heart J. 2013;34:2557-2565. doi: 10.1093/eurheartj/ehs056.
42. O'Reilly VC, Lopes Floro K, Shi H, Chapman BE, Preis JI, James AC, Chapman G, Harvey RP, Johnson RS, Grieve SM, Sparrow DB, Dunwoodie SL. Gene-environment interaction demonstrates the vulnerability of the embryonic heart. Dev Biol. 2014;391:99-110. doi: 10.1016/j. ydbio.2014.03.005.
43. Ingalls TH, Curley FJ, Prindle RA. Experimental production of congenital anomalies; timing and degree of anoxia as factors causing fetal deaths and congenital anomalies in the mouse. N Engl J Med. 1952;247:758-768. doi: 10.1056/NEJM195211132472004.
44. Sparrow DB, Chapman G, Smith AJ, Mattar MZ, Major JA, O'Reilly VC, Saga Y, Zackai EH, Dormans JP, Alman BA, McGregor L, Kageyama R, Kusumi K, Dunwoodie SL. A mechanism for gene-environment interaction in the etiology of congenital scoliosis. Cell. 2012;149:295-306. doi: 10.1016/j.cell.2012.02.054.
45. Webster WS, Abela D. The effect of hypoxia in development. Birth Defects Res C Embryo Today. 2007;81:215-228. doi: 10.1002/bdrc.20102.
46. van der Linde D, Konings EE, Slager MA, Witsenburg M, Helbing WA, Takkenberg JJ, Roos-Hesselink JW. Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis. J Am Coll Cardiol. 2011;58:2241-2247. doi: 10.1016/j.jacc.2011.08.025.
47. Gonzales GF. Peruvian contributions to the study on human reproduction at high altitude: from the chronicles of the Spanish conquest to the present. Respir Physiol Neurobiol. 2007;158:172-179. doi: 10.1016/j. resp.2007.03.015.
48. Moore LG, Charles SM, Julian CG. Humans at high altitude: hypoxia and fetal growth. Respir Physiol Neurobiol. 2011;178:181-190. doi: 10.1016/j.resp.2011.04.017.
49. Douglas CG, Haldane JS, Henderson Y, Schneider EC, Webb GB, Richards J. Physiological observations made on Pike's Peak, Colorado, with special reference to adaptation to low barometric pressures. Philos Trans R Soc Lond B. 1913;203:185-318.
50. Euler USV, Liljestrand G. Observations on the pulmonary arterial blood pressure in the cat. Acta Physiologica Scandinavica. 1946;12:301-320
51. Moudgil R, Michelakis ED, Archer SL. The role of k+ channels in determining pulmonary vascular tone, oxygen sensing, cell proliferation, and apoptosis: implications in hypoxic pulmonary vasoconstriction and pulmonary arterial hypertension. Microcirculation. 2006;13:615-632. doi: 10.1080/10739680600930222.
52. Shimoda LA, Polak J. Hypoxia. 4. Hypoxia and ion channel function. Am J Physiol Cell Physiol. 2011;300:C951-C967. doi: 10.1152/ ajpcell.00512.2010.
53. Kemp PJ, Peers C. Oxygen sensing by ion channels. Essays Biochem. 2007;43:77-90. doi: 10.1042/BSE0430077.
54. López-Barneo J, López-López JR, Ureña J, González C. Chemotransduction in the carotid body: K+ current modulated by PO2 in type I chemoreceptor cells. Science. 1988;241:580-582.
55. Cockman ME, Webb JD, Kramer HB, Kessler BM, Ratcliffe PJ. Proteomics-based identification of novel factor inhibiting hypoxia-inducible factor (FIH) substrates indicates widespread asparaginyl hydroxylation of ankyrin repeat domain-containing proteins. Mol Cell Proteomics. 2009;8:535-546. doi: 10.1074/mcp.M800340-MCP200.
56. Karttunen S, Duffield M, Scrimgeour NR, Squires L, Lim WL, Dallas ML, Scragg JL, Chicher J, Dave KA, Whitelaw ML, Peers C, Gorman JJ, Gleadle JM, Rychkov GY, Peet DJ. Oxygen-dependent hydroxylation by FIH regulates the TRPV3 ion channel. J Cell Sci. 2015;128:225-231. doi: 10.1242/jcs.158451.
57. Takahashi N, Kuwaki T, Kiyonaka S, et al. TRPA1 underlies a sensing mechanism for O2. Nat Chem Biol. 2011;7:701-711. doi: 10.1038/ nchembio.640.
58. Ortega-Sáenz P, Pascual A, Piruat JI, López-Barneo J. Mechanisms of acute oxygen sensing by the carotid body: lessons from genetically modified animals. Respir Physiol Neurobiol. 2007;157:140-147. doi: 10.1016/j. resp.2007.02.009.
59. Bishop T, Talbot NP, Turner PJ, Nicholls LG, Pascual A, Hodson EJ, Douglas G, Fielding JW, Smith TG, Demetriades M, Schofield CJ, Robbins PA, Pugh CW, Buckler KJ, Ratcliffe PJ. Carotid body hyperplasia and enhanced ventilatory responses to hypoxia in mice with heterozygous deficiency of PHD2. J Physiol. 2013;591:3565-3577. doi: 10.1113/ jphysiol.2012.247254.
60. Prabhakar NR, Semenza GL. Adaptive and maladaptive cardiorespiratory responses to continuous and intermittent hypoxia mediated by hypoxiainducible factors 1 and 2. Physiol Rev. 2012;92:967-1003. doi: 10.1152/ physrev.00030.2011.
61. Yu AY, Shimoda LA, Iyer NV, Huso DL, Sun X, McWilliams R, Beaty T, Sham JS, Wiener CM, Sylvester JT, Semenza GL. Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1alpha. J Clin Invest. 1999;103:691-696. doi: 10.1172/JCI5912.
62. Brusselmans K, Compernolle V, Tjwa M, Wiesener MS, Maxwell PH, Collen D, Carmeliet P. Heterozygous deficiency of hypoxia-inducible factor-2alpha protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia. J Clin Invest. 2003;111:1519-1527. doi: 10.1172/JCI15496.
63. Tan Q, Kerestes H, Percy MJ, Pietrofesa R, Chen L, Khurana TS, Christofidou-Solomidou M, Lappin TR, Lee FS. Erythrocytosis and pulmonary hypertension in a mouse model of human HIF2A gain of function mutation. J Biol Chem. 2013;288:17134-17144. doi: 10.1074/jbc. M112.444059.
64. Hickey MM, Richardson T, Wang T, Mosqueira M, Arguiri E, Yu H, Yu QC, Solomides CC, Morrisey EE, Khurana TS, Christofidou-Solomidou M, Simon MC. The von Hippel-Lindau Chuvash mutation promotes pulmonary hypertension and fibrosis in mice. J Clin Invest. 2010;120:827-839. doi: 10.1172/JCI36362.
65. Ang SO, Chen H, Hirota K, Gordeuk VR, Jelinek J, Guan Y, Liu E, Sergueeva AI, Miasnikova GY, Mole D, Maxwell PH, Stockton DW, Semenza GL, Prchal JT. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet. 2002;32:614-621. doi: 10.1038/ng1019.
66. Wang J, Weigand L, Lu W, Sylvester JT, Semenza GL, Shimoda LA. Hypoxia inducible factor 1 mediates hypoxia-induced TRPC expression and elevated intracellular Ca2+ in pulmonary arterial smooth muscle cells. Circ Res. 2006;98:1528-1537. doi: 10.1161/01. RES.0000227551.68124.98.
67. Quinn DA, Dahlberg CG, Bonventre JP, Scheid CR, Honeyman T, Joseph PM, Thompson BT, Hales CA. The role of Na+/H+ exchange and growth factors in pulmonary artery smooth muscle cell proliferation. Am J Respir Cell Mol Biol. 1996;14:139-145. doi: 10.1165/ajrcmb.14.2.8630263.
68. Shimoda LA, Laurie SS. HIF and pulmonary vascular responses to hypoxia. J Appl Physiol (1985). 2014;116:867-874. doi: 10.1152/ japplphysiol.00643.2013.
69. Pisarcik S, Maylor J, Lu W, Yun X, Undem C, Sylvester JT, Semenza GL, Shimoda LA. Activation of hypoxia-inducible factor-1 in pulmonary arterial smooth muscle cells by endothelin-1. Am J Physiol Lung Cell Mol Physiol. 2013;304:L549-L561. doi: 10.1152/ajplung.00081.2012.
70. Wiesener MS, Jürgensen JS, Rosenberger C, Scholze CK, Hörstrup JH, Warnecke C, Mandriota S, Bechmann I, Frei UA, Pugh CW, Ratcliffe PJ, Bachmann S, Maxwell PH, Eckardt KU. Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs. FASEB J. 2003;17:271-273. doi: 10.1096/fj.02-0445fje.
71. Skuli N, Liu L, Runge A, Wang T, Yuan L, Patel S, Iruela-Arispe L, Simon MC, Keith B. Endothelial deletion of hypoxia-inducible factor-2alpha (HIF-2alpha) alters vascular function and tumor angiogenesis. Blood. 2009;114:469-477. doi: 10.1182/blood-2008-12-193581.
72. Ball MK, Waypa GB, Mungai PT, Nielsen JM, Czech L, Dudley VJ, Beussink L, Dettman RW, Berkelhamer SK, Steinhorn RH, Shah SJ, Schumacker PT. Regulation of hypoxia-induced pulmonary hypertension by vascular smooth muscle hypoxia-inducible factor-1α. Am J Respir Crit Care Med. 2014;189:314-324. doi: 10.1164/rccm.201302-0302OC.
73. Kim YM, Barnes EA, Alvira CM, Ying L, Reddy S, Cornfield DN. Hypoxiainducible factor-1α in pulmonary artery smooth muscle cells lowers vascular tone by decreasing myosin light chain phosphorylation. Circ Res. 2013;112:1230-1233. doi: 10.1161/CIRCRESAHA.112.300646.
74. Franke K, Gassmann M, Wielockx B. Erythrocytosis: the HIF pathway in control. Blood. 2013;122:1122-1128. doi: 10.1182/ blood-2013-01-478065.
75. Lee FS, Percy MJ. The HIF pathway and erythrocytosis. Annu Rev Pathol. 2011;6:165-192. doi: 10.1146/annurev-pathol-011110-130321.
76. Smith TG, Brooks JT, Balanos GM, et al. Mutation of von Hippel-Lindau tumour suppressor and human cardiopulmonary physiology. PLoS Med. 2006;3:e290. doi: 10.1371/journal.pmed.0030290.
77. Bushuev VI, Miasnikova GY, Sergueeva AI, Polyakova LA, Okhotin D, Gaskin PR, Debebe Z, Nekhai S, Castro OL, Prchal JT, Gordeuk VR. Endothelin-1, vascular endothelial growth factor and systolic pulmonary artery pressure in patients with Chuvash polycythemia. Haematologica. 2006;91:744-749.
78. Gale DP, Harten SK, Reid CD, Tuddenham EG, Maxwell PH. Autosomal dominant erythrocytosis and pulmonary arterial hypertension associated with an activating HIF2 alpha mutation. Blood. 2008;112:919-921. doi: 10.1182/blood-2008-04-153718.
79. Formenti F, Beer PA, Croft QP, et al. Cardiopulmonary function in two human disorders of the hypoxia-inducible factor (HIF) pathway: von Hippel-Lindau disease and HIF-2alpha gain-of-function mutation. FASEB J. 2011;25:2001-2011. doi: 10.1096/fj.10-177378.
80. Beall CM, Cavalleri GL, Deng L, et al. Natural selection on EPAS1 (HIF2alpha) associated with low hemoglobin concentration in Tibetan highlanders. Proc Natl Acad Sci U S A. 2010;107:11459-11464. doi: 10.1073/pnas.1002443107.
81. Simonson TS, Yang Y, Huff CD, Yun H, Qin G, Witherspoon DJ, Bai Z, Lorenzo FR, Xing J, Jorde LB, Prchal JT, Ge R. Genetic evidence for high-altitude adaptation in Tibet. Science. 2010;329:72-75. doi: 10.1126/ science.1189406.
82. Petousi N, Croft QP, Cavalleri GL, Cheng HY, Formenti F, Ishida K, Lunn D, McCormack M, Shianna KV, Talbot NP, Ratcliffe PJ, Robbins PA. Tibetans living at sea level have a hyporesponsive hypoxia-inducible factor system and blunted physiological responses to hypoxia. J Appl Physiol (1985). 2014;116:893-904. doi: 10.1152/japplphysiol.00535.2013.
83. Lorenzo FR, Huff C, Myllymäki M, et al. A genetic mechanism for Tibetan high-altitude adaptation. Nat Genet. 2014;46:951-956. doi: 10.1038/ng.3067.
84. Franke K, Kalucka J, Mamlouk S, et al. HIF-1α is a protective factor in conditional PHD2-deficient mice suffering from severe HIF-2α-induced excessive erythropoiesis. Blood. 2013;121:1436-1445. doi: 10.1182/ blood-2012-08-449181.
85. Warnecke C, Zaborowska Z, Kurreck J, Erdmann VA, Frei U, Wiesener M, Eckardt KU. Differentiating the functional role of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha (EPAS-1) by the use of RNA interference: erythropoietin is a HIF-2alpha target gene in Hep3B and Kelly cells. FASEB J. 2004;18:1462-1464. doi: 10.1096/fj.04-1640fje.
86. Hirsilä M, Koivunen P, Günzler V, Kivirikko KI, Myllyharju J. Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. J Biol Chem. 2003;278:30772-30780. doi: 10.1074/jbc.M304982200.
87. Wang GL, Semenza GL. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. Blood. 1993;82:3610-3615.
88. Balanos GM, Dorrington KL, Robbins PA. Desferrioxamine elevates pulmonary vascular resistance in humans: potential for involvement of HIF-1. J Appl Physiol (1985). 2002;92:2501-2507. doi: 10.1152/ japplphysiol.00965.2001.
89. Smith TG, Balanos GM, Croft QP, Talbot NP, Dorrington KL, Ratcliffe PJ, Robbins PA. The increase in pulmonary arterial pressure caused by hypoxia depends on iron status. J Physiol. 2008;586:5999-6005. doi: 10.1113/jphysiol.2008.160960.
90. Smith TG, Talbot NP, Privat C, Rivera-Ch M, Nickol AH, Ratcliffe PJ, Dorrington KL, León-Velarde F, Robbins PA. Effects of iron supplementation and depletion on hypoxic pulmonary hypertension: two randomized controlled trials. JAMA. 2009;302:1444-1450. doi: 10.1001/ jama.2009.1404.
91. Ruiter G, Lankhorst S, Boonstra A, Postmus PE, Zweegman S, Westerhof N, van der Laarse WJ, Vonk-Noordegraaf A. Iron deficiency is common in idiopathic pulmonary arterial hypertension. Eur Respir J. 2011;37:1386-1391. doi: 10.1183/09031936.00100510.
92. Bishop T, Gallagher D, Pascual A, et al. Abnormal sympathoadrenal development and systemic hypotension in PHD3-/- mice. Mol Cell Biol. 2008;28:3386-3400. doi: 10.1128/MCB.02041-07.
93. Cowburn AS, Takeda N, Boutin AT, Kim JW, Sterling JC, Nakasaki M, Southwood M, Goldrath AW, Jamora C, Nizet V, Chilvers ER, Johnson RS. HIF isoforms in the skin differentially regulate systemic arterial pressure. Proc Natl Acad Sci U S A. 2013;110:17570-17575. doi: 10.1073/ pnas.1306942110.
94. Peng YJ, Nanduri J, Khan SA, Yuan G, Wang N, Kinsman B, Vaddi DR, Kumar GK, Garcia JA, Semenza GL, Prabhakar NR. Hypoxia-inducible factor 2α (HIF-2α) heterozygous-null mice exhibit exaggerated carotid body sensitivity to hypoxia, breathing instability, and hypertension. Proc Natl Acad Sci U S A. 2011;108:3065-3070. doi: 10.1073/ pnas.1100064108.
95. McClain DA, Abuelgasim KA, Nouraie M, et al. Decreased serum glucose and glycosylated hemoglobin levels in patients with Chuvash polycythemia: a role for HIF in glucose metabolism. J Mol Med (Berl). 2013;91:59-67. doi: 10.1007/s00109-012-0961-5.
96. Flamme I, Oehme F, Ellinghaus P, Jeske M, Keldenich J, Thuss U. Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects. PLoS One. 2014;9:e111838. doi: 10.1371/journal.pone.0111838.
97. Willam C, Maxwell PH, Nichols L, Lygate C, Tian YM, Bernhardt W, Wiesener M, Ratcliffe PJ, Eckardt KU, Pugh CW. HIF prolyl hydroxylases in the rat; organ distribution and changes in expression following hypoxia and coronary artery ligation. J Mol Cell Cardiol. 2006;41:68-77. doi: 10.1016/j.yjmcc.2006.04.009.
98. Jürgensen JS, Rosenberger C, Wiesener MS, Warnecke C, Hörstrup JH, Gräfe M, Philipp S, Griethe W, Maxwell PH, Frei U, Bachmann S, Willenbrock R, Eckardt KU. Persistent induction of HIF-1alpha and -2alpha in cardiomyocytes and stromal cells of ischemic myocardium. FASEB J. 2004;18:1415-1417. doi: 10.1096/fj.04-1605fje.
99. Rosenberger C, Mandriota S, Jürgensen JS, Wiesener MS, Hörstrup JH, Frei U, Ratcliffe PJ, Maxwell PH, Bachmann S, Eckardt KU. Expression of hypoxia-inducible factor-1alpha and -2alpha in hypoxic and ischemic rat kidneys. J Am Soc Nephrol. 2002;13:1721-1732.
100. Bishop T, Ratcliffe PJ. Signaling hypoxia by hypoxia-inducible factor protein hydroxylases: a historical overview and future perspectives. Hypoxia. 2014;2:197-213.
101. Tekin D, Dursun AD, Xi L. Hypoxia inducible factor 1 (HIF-1) and cardioprotection. Acta Pharmacol Sin. 2010;31:1085-1094. doi: 10.1038/ aps.2010.132.
102. Selvaraju V, Parinandi NL, Adluri RS, Goldman JW, Hussain N, Sanchez JA, Maulik N. Molecular mechanisms of action and therapeutic uses of pharmacological inhibitors of HIF-prolyl 4-hydroxylases for treatment of ischemic diseases. Antioxid Redox Signal. 2014;20:2631-2665. doi: 10.1089/ars.2013.5186.
103. Singh N, Sharma G, Mishra V. Hypoxia inducible factor-1: its potential role in cerebral ischemia. Cell Mol Neurobiol. 2012;32:491-507. doi: 10.1007/s10571-012-9803-9.
104. Reimer KA, Murry CE, Yamasawa I, Hill ML, Jennings RB. Four brief periods of myocardial ischemia cause no cumulative ATP loss or necrosis. Am J Physiol. 1986;251:H1306-H1315.
105. Kalakech H, Tamareille S, Pons S, Godin-Ribuot D, Carmeliet P, Furber A, Martin V, Berdeaux A, Ghaleh B, Prunier F. Role of hypoxia inducible factor-1α in remote limb ischemic preconditioning. J Mol Cell Cardiol. 2013;65:98-104. doi: 10.1016/j.yjmcc.2013.10.001.
106. Cai Z, Zhong H, Bosch-Marce M, Fox-Talbot K, Wang L, Wei C, Trush MA, Semenza GL. Complete loss of ischaemic preconditioning-induced cardioprotection in mice with partial deficiency of HIF-1 alpha. Cardiovasc Res. 2008;77:463-470. doi: 10.1093/cvr/cvm035.
107. Eckle T, Köhler D, Lehmann R, El Kasmi K, Eltzschig HK. Hypoxiainducible factor-1 is central to cardioprotection: a new paradigm for ischemic preconditioning. Circulation. 2008;118:166-175. doi: 10.1161/ CIRCULATIONAHA.107.758516.
108. Cai Z, Manalo DJ, Wei G, Rodriguez ER, Fox-Talbot K, Lu H, Zweier JL, Semenza GL. Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation. 2003;108:79-85. doi: 10.1161/01.CIR.0000078635.89229.8A.
109. Cai Z, Luo W, Zhan H, Semenza GL. Hypoxia-inducible factor 1 is required for remote ischemic preconditioning of the heart. Proc Natl Acad Sci U S A. 2013;110:17462-17467. doi: 10.1073/pnas.1317158110.
110. Semenza GL. Hypoxia-inducible factor 1: regulator of mitochondrial metabolism and mediator of ischemic preconditioning. Biochim Biophys Acta. 2011;1813:1263-1268. doi: 10.1016/j.bbamcr.2010.08.006.
111. Kido M, Du L, Sullivan CC, Li X, Deutsch R, Jamieson SW, Thistlethwaite PA. Hypoxia-inducible factor 1-alpha reduces infarction and attenuates progression of cardiac dysfunction after myocardial infarction in the mouse. J Am Coll Cardiol. 2005;46:2116-2124. doi: 10.1016/j.jacc.2005.08.045.
112. Huang M, Chan DA, Jia F, Xie X, Li Z, Hoyt G, Robbins RC, Chen X, Giaccia AJ, Wu JC. Short hairpin RNA interference therapy for ischemic heart disease. Circulation. 2008;118:S226-S233. doi: 10.1161/ CIRCULATIONAHA.107.760785.
113. Hölscher M, Silter M, Krull S, von Ahlen M, Hesse A, Schwartz P, Wielockx B, Breier G, Katschinski DM, Zieseniss A. Cardiomyocytespecific prolyl-4-hydroxylase domain 2 knock out protects from acute myocardial ischemic injury. J Biol Chem. 2011;286:11185-11194. doi: 10.1074/jbc.M110.186809.
114. Hyvärinen J, Hassinen IE, Sormunen R, Mäki JM, Kivirikko KI, Koivunen P, Myllyharju J. Hearts of hypoxia-inducible factor prolyl 4-hydroxylase-2 hypomorphic mice show protection against acute ischemia-reperfusion injury. J Biol Chem. 2010;285:13646-13657. doi: 10.1074/jbc.M109.084855.
115. Kerkelä R, Karsikas S, Szabo Z, Serpi R, Magga J, Gao E, Alitalo K, Anisimov A, Sormunen R, Pietilä I, Vainio L, Koch WJ, Kivirikko KI, Myllyharju J, Koivunen P. Activation of hypoxia response in endothelial cells contributes to ischemic cardioprotection. Mol Cell Biol. 2013;33:3321-3329. doi: 10.1128/MCB.00432-13.
116. Adluri RS, Thirunavukkarasu M, Dunna NR, Zhan L, Oriowo B, Takeda K, Sanchez JA, Otani H, Maulik G, Fong GH, Maulik N. Disruption of hypoxia-inducible transcription factor-prolyl hydroxylase domain-1 (PHD- 1-/-) attenuates ex vivo myocardial ischemia/reperfusion injury through hypoxia- inducible factor-1α transcription factor and its target genes in mice. Antioxid Redox Signal. 2011;15:1789-1797. doi: 10.1089/ars.2010.3769.
117. Natarajan R, Salloum FN, Fisher BJ, Kukreja RC, Fowler AA 3rd. Hypoxia inducible factor-1 activation by prolyl 4-hydroxylase-2 gene silencing attenuates myocardial ischemia reperfusion injury. Circ Res. 2006;98:133-140. doi: 10.1161/01.RES.0000197816.63513.27.
118. Natarajan R, Salloum FN, Fisher BJ, Ownby ED, Kukreja RC, Fowler AA 3rd. Activation of hypoxia-inducible factor-1 via prolyl-4 hydoxylase-2 gene silencing attenuates acute inflammatory responses in postischemic myocardium. Am J Physiol Heart Circ Physiol. 2007;293:H1571-H1580. doi: 10.1152/ajpheart.00291.2007.
119. Ong SG, Lee WH, Theodorou L, Kodo K, Lim SY, Shukla DH, Briston T, Kiriakidis S, Ashcroft M, Davidson SM, Maxwell PH, Yellon DM, Hausenloy DJ. HIF-1 reduces ischaemia-reperfusion injury in the heart by targeting the mitochondrial permeability transition pore. Cardiovasc Res. 2014;104:24-36. doi: 10.1093/cvr/cvu172.
120. Xie L, Pi X, Wang Z, He J, Willis MS, Patterson C. Depletion of PHD3 protects heart from ischemia/reperfusion injury by inhibiting cardiomyocyte apoptosis. J Mol Cell Cardiol. 2015;80:156-165. doi: 10.1016/j. yjmcc.2015.01.007.
121. Hölscher M, Schäfer K, Krull S, Farhat K, Hesse A, Silter M, Lin Y, Pichler BJ, Thistlethwaite P, El-Armouche A, Maier LS, Katschinski DM, Zieseniss A. Unfavourable consequences of chronic cardiac HIF-1α stabilization. Cardiovasc Res. 2012;94:77-86. doi: 10.1093/cvr/cvs014.
122. Moslehi J, Minamishima YA, Shi J, Neuberg D, Charytan DM, Padera RF, Signoretti S, Liao R, Kaelin WG Jr. Loss of hypoxia-inducible factor prolyl hydroxylase activity in cardiomyocytes phenocopies ischemic cardiomyopathy. Circulation. 2010;122:1004-1016. doi: 10.1161/ CIRCULATIONAHA.109.922427.
123. Bekeredjian R, Walton CB, MacCannell KA, Ecker J, Kruse F, Outten JT, Sutcliffe D, Gerard RD, Bruick RK, Shohet RV. Conditional HIF- 1alpha expression produces a reversible cardiomyopathy. PLoS One. 2010;5:e11693. doi: 10.1371/journal.pone.0011693.
124. Dendorfer A, Heidbreder M, Hellwig-Bürgel T, Jöhren O, Qadri F, Dominiak P. Deferoxamine induces prolonged cardiac preconditioning via accumulation of oxygen radicals. Free Radic Biol Med. 2005;38:117-124. doi: 10.1016/j.freeradbiomed.2004.10.015.
125. Vogler M, Zieseniss A, Hesse AR, Levent E, Tiburcy M, Heinze E, Burzlaff N, Schley G, Eckardt KU, Willam C, Katschinski DM. Pre- and post-conditional inhibition of prolyl-4-hydroxylase domain enzymes protects the heart from an ischemic insult [published online ahead of print January 13, 2015]. Pflügers Arch. doi: 10.1007/s00424-014-1667-z. http://link.springer.com/article/10.1007%2Fs00424-014-1667-z.
126. Xi L, Taher M, Yin C, Salloum F, Kukreja RC. Cobalt chloride induces delayed cardiac preconditioning in mice through selective activation of HIF-1alpha and AP-1 and iNOS signaling. Am J Physiol Heart Circ Physiol. 2004;287:H2369-H2375. doi: 10.1152/ajpheart.00422.2004.
127. Ockaili R, Natarajan R, Salloum F, Fisher BJ, Jones D, Fowler AA 3rd, Kukreja RC. HIF-1 activation attenuates postischemic myocardial injury: role for heme oxygenase-1 in modulating microvascular chemokine generation. Am J Physiol Heart Circ Physiol. 2005;289:H542-H548. doi: 10.1152/ajpheart.00089.2005.
128. Zhao HX, Wang XL, Wang YH, Wu Y, Li XY, Lv XP, Zhao ZQ, Zhao RR, Liu HR. Attenuation of myocardial injury by postconditioning: role of hypoxia inducible factor-1alpha. Basic Res Cardiol. 2010;105:109-118. doi: 10.1007/s00395-009-0044-0.
129. Nwogu NI, Greenen D, Bean M, Brenner MC, Huang X, Buttrick PM. Inhibition of collagen synthesis with prolyl 4-hydroxylase inhibitor improves left ventricular function and alters the pattern of left ventricular dilatation after myocardial infarction. Circulation. 2001;104:2216-2221
130. Philipp S, Jürgensen JS, Fielitz J, Bernhardt WM, Weidemann A, Schiche A, Pilz B, Dietz R, Regitz-Zagrosek V, Eckardt KU, Willenbrock R. Stabilization of hypoxia inducible factor rather than modulation of collagen metabolism improves cardiac function after acute myocardial infarction in rats. Eur J Heart Fail. 2006;8:347-354. doi: 10.1016/j.ejheart.2005.10.009.
131. Bao W, Qin P, Needle S, Erickson-Miller CL, Duffy KJ, Ariazi JL, Zhao S, Olzinski AR, Behm DJ, Pipes GC, Jucker BM, Hu E, Lepore JJ, Willette RN. Chronic inhibition of hypoxia-inducible factor prolyl 4-hydroxylase improves ventricular performance, remodeling, and vascularity after myocardial infarction in the rat. J Cardiovasc Pharmacol. 2010;56:147-155. doi: 10.1097/FJC.0b013e3181e2bfef.
132. Tian YM, Yeoh KK, Lee MK, Eriksson T, Kessler BM, Kramer HB, Edelmann MJ, Willam C, Pugh CW, Schofield CJ, Ratcliffe PJ. Differential sensitivity of hypoxia inducible factor hydroxylation sites to hypoxia and hydroxylase inhibitors. J Biol Chem. 2011;286:13041-13051. doi: 10.1074/jbc.M110.211110.
133. Wang Z, Schley G, Türkoglu G, Burzlaff N, Amann KU, Willam C, Eckardt KU, Bernhardt WM. The protective effect of prolyl-hydroxylase inhibition against renal ischaemia requires application prior to ischaemia but is superior to EPO treatment. Nephrol Dial Transplant. 2012;27:929-936. doi: 10.1093/ndt/gfr379.
134. Natarajan R, Salloum FN, Fisher BJ, Smithson L, Almenara J, Fowler AA 3rd. Prolyl hydroxylase inhibition attenuates post-ischemic cardiac injury via induction of endoplasmic reticulum stress genes. Vascul Pharmacol. 2009;51:110-118. doi: 10.1016/j.vph.2009.05.007.
135. Lei L, Mason S, Liu D, Huang Y, Marks C, Hickey R, Jovin IS, Pypaert M, Johnson RS, Giordano FJ. Hypoxia-inducible factor-dependent degeneration, failure, and malignant transformation of the heart in the absence of the von Hippel-Lindau protein. Mol Cell Biol. 2008;28:3790-3803. doi: 10.1128/MCB.01580-07.
136. Beuck S, Schänzer W, Thevis M. Hypoxia-inducible factor stabilizers and other small-molecule erythropoiesis-stimulating agents in current and preventive doping analysis. Drug Test Anal. 2012;4:830-845. doi: 10.1002/dta.390.
137. Nizet V, Johnson RS. Interdependence of hypoxic and innate immune responses. Nat Rev Immunol. 2009;9:609-617. doi: 10.1038/nri2607.
138. Vink A, Schoneveld AH, Lamers D, Houben AJ, van der Groep P, van Diest PJ, Pasterkamp G. HIF-1 alpha expression is associated with an atheromatous inflammatory plaque phenotype and upregulated in activated macrophages. Atherosclerosis. 2007;195:e69-e75. doi: 10.1016/j. atherosclerosis.2007.05.026.
139. Nguyen AQ, Cherry BH, Scott GF, Ryou MG, Mallet RT. Erythropoietin: powerful protection of ischemic and post-ischemic brain. Exp Biol Med (Maywood). 2014;239:1461-1475. doi: 10.1177/1535370214523703.
140. Lapchak PA. Erythropoietin molecules to treat acute ischemic stroke: a translational dilemma! Expert Opin Investig Drugs. 2010;19:1179-1186. doi: 10.1517/13543784.2010.517954.
141. McCullough PA, Barnhart HX, Inrig JK, Reddan D, Sapp S, Patel UD, Singh AK, Szczech LA, Califf RM. Cardiovascular toxicity of epoetinalfa in patients with chronic kidney disease. Am J Nephrol. 2013;37:549-558. doi: 10.1159/000351175.
142. Rabinowitz MH. Inhibition of hypoxia-inducible factor prolyl hydroxylase domain oxygen sensors: tricking the body into mounting orchestrated survival and repair responses. J Med Chem. 2013;56:9369-9402. doi: 10.1021/jm400386j.
143. Fraisl P, Aragonés J, Carmeliet P. Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease. Nat Rev Drug Discov. 2009;8:139-152. doi: 10.1038/nrd2761.
144. Safran M, Kim WY, O'Connell F, Flippin L, Günzler V, Horner JW, Depinho RA, Kaelin WG Jr. Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin production. Proc Natl Acad Sci U S A. 2006;103:105-110. doi: 10.1073/pnas.0509459103.
145. Yan L, Colandrea VJ, Hale JJ. Prolyl hydroxylase domain-containing protein inhibitors as stabilizers of hypoxia-inducible factor: small molecule-based therapeutics for anemia. Expert Opin Ther Pat. 2010;20:1219-1245. doi: 10.1517/13543776.2010.510836.
146. Chan M, Atasoylu O, Hodson EJ, et al. Potent, selective, and blood-brain barrier permeating triazole-based inhibitors of the hypoxia-inducible factor prolyl-hydroxylases. PLoS ONE. 2015.